Claro Advisors LLC Sells 384 Shares of Illumina, Inc. (NASDAQ:ILMN)

Claro Advisors LLC decreased its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 17.2% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,848 shares of the life sciences company’s stock after selling 384 shares during the quarter. Claro Advisors LLC’s holdings in Illumina were worth $247,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Empowered Funds LLC grew its stake in shares of Illumina by 1.7% in the third quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company’s stock valued at $516,000 after buying an additional 66 shares in the last quarter. Caprock Group LLC lifted its stake in Illumina by 3.0% in the third quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company’s stock valued at $376,000 after acquiring an additional 83 shares during the last quarter. Integrated Advisors Network LLC grew its position in shares of Illumina by 2.0% in the 3rd quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock valued at $585,000 after acquiring an additional 90 shares during the period. Moors & Cabot Inc. increased its stake in shares of Illumina by 1.7% during the 3rd quarter. Moors & Cabot Inc. now owns 5,818 shares of the life sciences company’s stock worth $759,000 after purchasing an additional 95 shares during the last quarter. Finally, Carson Advisory Inc. increased its stake in shares of Illumina by 3.8% during the 3rd quarter. Carson Advisory Inc. now owns 2,757 shares of the life sciences company’s stock worth $360,000 after purchasing an additional 102 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

ILMN has been the subject of several recent analyst reports. UBS Group raised their target price on shares of Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. JPMorgan Chase & Co. lifted their target price on Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Barclays increased their price target on Illumina from $135.00 to $145.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. Citigroup cut shares of Illumina from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $190.00 to $165.00 in a research report on Wednesday, December 11th. Finally, HSBC raised shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 price objective on the stock in a research report on Thursday, October 17th. Eight research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $165.63.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $136.19 on Thursday. The business has a fifty day moving average price of $140.55 and a two-hundred day moving average price of $133.10. The stock has a market capitalization of $21.60 billion, a PE ratio of -13.67 and a beta of 1.11. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. Illumina, Inc. has a fifty-two week low of $100.08 and a fifty-two week high of $156.66.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.26. The business had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. Illumina’s revenue was down 3.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.33 earnings per share. As a group, equities analysts predict that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.